Xylyx Bio develops bioengineered human organ grafts, known as Inspirex® organs, to increase the availability of transplantable organs. This technology addresses the critical shortage of donor organs, with millions of patients in need and many viable organs going unused due to compatibility issues.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The severe shortage of transplantable human organs results in a significant number of deaths and diminished quality of life for patients with end-stage organ failure. Many potentially viable donor organs are discarded due to compatibility issues or damage, further exacerbating the crisis.
Solution
Xylyx Bio is developing Inspirex® bioengineered human organ grafts to increase the availability of organs for transplantation. These personalized organs are designed to overcome compatibility challenges and expand the pool of usable organs. By bioengineering functional, anatomically compatible whole organ grafts, Xylyx Bio aims to transform transplant medicine and save lives. The company focuses on rehabilitating and recovering previously unusable human donor organs through advanced bioengineering techniques.
Target Audience
The primary target audience includes patients with end-stage organ failure awaiting transplantation, transplant centers, and medical professionals involved in organ transplantation.
Features
- Bioengineering of personalized human organ grafts
- Development of Inspirex™ Lung and Inspirex™ Liver grafts
- Organ rehabilitation and recovery methodologies
- Addressing organ compatibility issues